Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Amylin is a hormone that helps regulate blood sugar levels and control appetite, while calcitonin is a metabolic hormone.

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

The first amylin drug was introduced to the market some 20 years ago ... The Danish drugmaker has already struggled to meet ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

The company is investing in the development of longer-acting analogs and investigating the potential of Amylin in treating metabolic diseases. The obesity market, in particular, represents a ...

LAUNCESTON, Australia, Oct 24 (Reuters) - China is adding renewable energies such as wind and solar to its electricity grid at a record pace, but it is also boosting the use of coal-fired ...